by John Conrad | Oct 21, 2021 | Policy News
The Illinois General Assembly returned to Springfield this week, and both chambers convened Tuesday and Wednesday. During that time, there was limited committee and floor action in both chambers. The House and Senate were scheduled to convene tomorrow, but both...
by John Conrad | Oct 18, 2021 | Policy News
We need our elected leaders to lower patients’ out-of-pocket cost for innovative prescription drugs. Unfortunately, Congress is considering radical government price setting policies. If enacted, these provisions would: Drastically limit patient access to...
by John Conrad | Sep 20, 2021 | iBIO News, Policy News
The Illinois biosciences community is experiencing a renaissance. Fueled by public and private investment and the passion of our community’s members, we are experiencing unprecedented growth, For example, nearly one million square feet of Class A lab space currently...
by John Conrad | Aug 6, 2021 | Policy News
Last week Governor Pritzker signed HB HB 1779 that would require state-regulated plans to cover biomarker testing starting in 2022. The bill was introduced by Representative Mary Flowers (D-31st) in the House and Senator Antonio Muñoz (D-1st) in the Senate....
by John Conrad | Apr 22, 2021 | iBIO News, Policy News, PolicyFeature1
Fewer drugs for cancer, diabetes, rare diseases, and other conditions would be developed, and Illinois would lose 58,065 jobs Today Energy and Commerce Committee Chairman Frank Pallone, Jr. (D-NJ), Ways and Means Committee Chairman Richard Neal (D-MA), and Education...
by John Conrad | Mar 24, 2021 | iBIO News, Policy News
Washington, D.C. (March 23, 2021) –The Council of State Bioscience Associations (CSBA) today (iBIO is a member of the CSBA and John Conrad serves on the board of directors), released data analyzing the potential impact of various drug pricing proposals on patient...
